These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26609863)

  • 21. [Pro-prostate-specific antigen and its related indexes in the diagnosis of prostate cancer].
    Jiang L; Lu YP
    Zhonghua Nan Ke Xue; 2015 Jul; 21(7):655-8. PubMed ID: 26333230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostate health index for the diagnosis of prostate cancer in Asians in Macau with a PSA level of 4－10 μg/L].
    Chang KN; Hu F; Zheng W; Kwan WW; Iam-Ting IP; Shrestha S; Chan TI
    Zhonghua Nan Ke Xue; 2021 Sep; 27(9):803-808. PubMed ID: 34914256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Index Outperform Prostate-Specific Antigen and the Percentage of Free Prostate-Specific Antigen in the Detection of Clinically Significant Prostate Cancer and Can Be Used as Reflex Tests.
    Garrido MM; Marta JC; Bernardino RM; Guerra J; Fernandes F; Pereira MH; Ribeiro R; Holdenrieder S; Pinheiro LC; Guimarães JT
    Arch Pathol Lab Med; 2022 Jun; 146(6):691-700. PubMed ID: 34343237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination.
    Dittadi R; Fabricio ASC; Rainato G; Peroni E; Di Tonno F; Vezzù B; Mazzariol C; Squarcina E; Tammone L; Gion M
    Clin Chem Lab Med; 2019 Mar; 57(4):521-531. PubMed ID: 30218601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
    Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
    Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
    Isharwal S; Makarov DV; Sokoll LJ; Landis P; Marlow C; Epstein JI; Partin AW; Carter HB; Veltri RW
    Urology; 2011 Mar; 77(3):763.e1-6. PubMed ID: 21216447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.
    Wang W; Wang M; Wang L; Adams TS; Tian Y; Xu J
    Sci Rep; 2014 May; 4():5012. PubMed ID: 24852453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.
    Ito K; Fujizuka Y; Ishikura K; Cook B
    Int J Clin Oncol; 2014 Oct; 19(5):782-92. PubMed ID: 25135462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.
    Makarov DV; Isharwal S; Sokoll LJ; Landis P; Marlow C; Epstein JI; Partin AW; Carter HB; Veltri RW
    Clin Cancer Res; 2009 Dec; 15(23):7316-21. PubMed ID: 19934305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study.
    Lazzeri M; Lughezzani G; Haese A; McNicholas T; de la Taille A; Buffi NM; Cardone P; Hurle R; Casale P; Bini V; Redorta JP; Graefen M; Guazzoni G
    Urol Oncol; 2016 Sep; 34(9):415.e13-9. PubMed ID: 27178729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients].
    Houlgatte A; Vincendeau S; Desfemmes F; Ramirez J; Benoist N; Bensalah K; Durand X
    Prog Urol; 2012 May; 22(5):279-83. PubMed ID: 22515924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
    Stephan C; Kahrs AM; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
    Prostate; 2009 Feb; 69(2):198-207. PubMed ID: 18942119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
    Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers.
    Garrido MM; Ribeiro R; Pinheiro LC; Holdenrieder S; Guimarães JT
    Clin Chem Lab Med; 2021 Oct; 59(11):1869-1877. PubMed ID: 34318651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.